Fundraise

Korea's Raywatt raises $9.74M Series B for cardiovascular imaging

What's the deal? RaywattDealroom has a profile for this one. Try Dealroom →, a South Korean cardiovascular and cerebrovascular imaging device maker, has closed a US$10.9M Series B round. The financing lifts its total raised past US$19.7M.

Who's backing it? Nine institutions joined, including IntervestDealroom has a profile for this one. Try Dealroom →, Life Asset ManagementDealroom has a profile for this one. Try Dealroom →, Yukyung PSG Asset ManagementDealroom has a profile for this one. Try Dealroom →, Hyundai Technology InvestmentDealroom has a profile for this one. Try Dealroom →, LS Venture Capital, Eugene Investment & Securities, Ecopro Partners, and Kaictu Ventures.

What does it build? Raywatt's flagship FASTER system is an optical coherence tomography (OCT) scanner that spins an intravascular catheter 400 times per second, delivering 400 high-resolution frames per second in real time. It can capture images using saline alone instead of contrast dye, cutting the risk of patient side effects.

What's the traction? The company passed 100 clinical cases at Severance Cardiovascular Hospital, won sales approval in Vietnam, and secured a tender for a UAE government hospital. FASTER OCT is in final review for US Food and Drug Administration 510(k) clearance.

What's the money for? The capital will fund a global supply chain after FDA approval, next-generation products including cerebrovascular OCT, and scaled-up manufacturing. Raywatt is targeting a Kosdaq listing in 2028.

What could go wrong? FDA clearance remains pending, making the round largely a commercialisation bet on approvals and hospital adoption rather than technology. Competition is sharpening: Abbott won FDA clearance for an AI-based OCT system in 2026, and PhilipsDealroom has a profile for this one. Try Dealroom → is strengthening its imaging offerings.

Why it matters: Raywatt, a 2019 spinout from a Sejong University research lab, shows local hardware startups pushing into a global medical-device market dominated by incumbents. The 2028 listing goal still rests on proving overseas revenue through regulatory approval — for now, a plan rather than a milestone.

Read more: wowtale.net

Image credit: "NMCSD Recognizes Cardiovascular Professionals Week" by U.S. Navy Medicine, public domain (CC0 1.0)

More top stories